The timing of immune checkpoint inhibitor infusions may be crucial to outcomes, according to findings from a study that found a significant survival benefit associated with daytime compared to evening administration of therapy for patients with advanced melanoma. In a retrospective study, oncologists at the Winship Cancer Institute of Emory University, Atlanta, Georgia, analysed outcomes ...
Survival benefit for daytime vs evening infusions of checkpoint inhibitors
By Michael Woodhead
15 Nov 2021